Cornercap Investment Counsel Inc. Has $58,000 Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Cornercap Investment Counsel Inc. decreased its stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 52.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 30,222 shares of the company’s stock after selling 33,616 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Tenaya Therapeutics were worth $58,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in TNYA. SG Americas Securities LLC bought a new stake in Tenaya Therapeutics during the third quarter valued at about $49,000. The Manufacturers Life Insurance Company grew its stake in shares of Tenaya Therapeutics by 43.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after acquiring an additional 7,000 shares during the last quarter. Algert Global LLC bought a new position in Tenaya Therapeutics during the second quarter worth $74,000. Panagora Asset Management Inc. acquired a new position in Tenaya Therapeutics during the 2nd quarter valued at $164,000. Finally, Rhumbline Advisers boosted its holdings in Tenaya Therapeutics by 10.5% in the 2nd quarter. Rhumbline Advisers now owns 78,160 shares of the company’s stock valued at $242,000 after purchasing an additional 7,441 shares during the period. 90.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TNYA. Canaccord Genuity Group restated a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a report on Friday, October 18th. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital decreased their price objective on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $14.75.

Tenaya Therapeutics Trading Up 4.6 %

TNYA stock opened at $2.06 on Tuesday. The firm has a market cap of $163.19 million, a P/E ratio of -1.43 and a beta of 2.34. Tenaya Therapeutics, Inc. has a 1-year low of $1.61 and a 1-year high of $7.01. The business’s 50 day moving average is $2.01 and its 200-day moving average is $2.92.

Tenaya Therapeutics (NASDAQ:TNYA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.07. Sell-side analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.